TrialJournal of the American Heart Association2025

Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial.

Gregory P Geba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.